Tango Therapeutics (NASDAQ:TNGX) Price Target Raised to $19.00 at Wedbush

Tango Therapeutics (NASDAQ:TNGX) had its price objective hoisted by Wedbush from $15.00 to $19.00 in a report released on Friday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other equities research analysts have also recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating and issued a $18.00 price objective on shares of Tango Therapeutics in a report on Thursday. HC Wainwright lifted their target price on shares of Tango Therapeutics from $13.00 to $27.00 and gave the company a “buy” rating in a report on Friday. Wolfe Research assumed coverage on Tango Therapeutics in a research report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Piper Sandler upped their price target on Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Finally, Mizuho started coverage on Tango Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $19.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.25.

Tango Therapeutics Trading Up 0.7%

Shares of TNGX stock opened at $16.95 on Friday. The company’s fifty day moving average price is $11.86 and its 200-day moving average price is $9.44. The stock has a market cap of $2.28 billion, a PE ratio of -19.48 and a beta of 1.76. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $17.63.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 66.01%. On average, sell-side analysts forecast that Tango Therapeutics will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Adam Crystal sold 54,345 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total value of $693,985.65. Following the completion of the transaction, the insider directly owned 132,873 shares in the company, valued at $1,696,788.21. The trade was a 29.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Daniella Beckman sold 10,317 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $126,486.42. Following the sale, the chief financial officer owned 184,297 shares in the company, valued at approximately $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 113,633 shares of company stock worth $1,420,857 in the last three months. Insiders own 7.50% of the company’s stock.

Institutional Trading of Tango Therapeutics

A number of large investors have recently made changes to their positions in TNGX. Legal & General Group Plc raised its holdings in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after purchasing an additional 1,640 shares during the last quarter. Russell Investments Group Ltd. grew its position in Tango Therapeutics by 26.7% in the 4th quarter. Russell Investments Group Ltd. now owns 9,794 shares of the company’s stock worth $87,000 after purchasing an additional 2,065 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after purchasing an additional 2,243 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Tango Therapeutics by 12.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,946 shares of the company’s stock valued at $194,000 after buying an additional 2,444 shares during the last quarter. Finally, Barclays PLC raised its stake in Tango Therapeutics by 0.7% during the 4th quarter. Barclays PLC now owns 368,187 shares of the company’s stock valued at $3,262,000 after buying an additional 2,507 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors.

Key Tango Therapeutics News

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.